Because this is an off-label use, insurance may not cover the weekly injections, which can be costly
Tirzepatide showed the greatest reduction in likelihood, with a 60% reduction, as seen in Figure 2
This concept of microdosing GLP-1s gained traction due to obesity drug shortages shortly after these new, highly effective medications were approved in 2021 and 2022
Among non-diabetic patients, those prescribed semaglutide had a lower likelihood of depression compared to those not prescribed the GLP-1 medication
GLP-1 receptor agonists are positioned as one of the pharmacotherapeutic options that can contribute to addressing the high unmet medical need characterizing several prevalent aging-related diseases, making them ideal for our longevity-focused approach
Those effectsreduced appetite, slower stomach-emptying and unexpected weight lossled the U } The Risks of Microdosing GLP-1s GLP-1 medications are powerful, but theyre not benign